Literature DB >> 27110731

Allergic-like Reactions to the MR Imaging Contrast Agent Gadobutrol: A Prospective Study of 32 991 Consecutive Injections.

Sarah Power1, Nancy Talbot1, Walter Kucharczyk1, Daniel M Mandell1.   

Abstract

Purpose To determine the frequency and severity of allergic-like reactions to gadobutrol. Materials and Methods Data collection during the study period was part of a hospital quality assurance initiative to confirm the safety of gadobutrol after its introduction at this institute from 2010 to 2013. The study also included an electronic health records review approved by the institutional review board of the University Health Network, Toronto. The institutional review board waived the requirement for informed consent. At the time of each reaction to contrast material, the patient's age and sex, whether premedication was given, the contrast agent used, the volume injected, the patient's symptoms, and the treatment administered were recorded. Allergic-like reactions from physiologic reactions were differentiated and the frequency and severity of allergic-like reactions, the prevalence of risk factors for reactions, the frequency of reactions despite the use of premedication (a "breakthrough reaction"), and the frequency of delayed reactions were calculated. A χ(2) test to determine whether there was a difference in reaction rates during the 4 years of the study was performed. Results The frequency of allergic-like reactions to gadobutrol was 0.32% (96 reactions among 30 373 gadobutrol-enhanced magnetic resonance [MR] imaging examinations) during the study period. These 96 reactions occurred in 82 patients. There was only one severe reaction. There were identifiable risk factors in 40 of the 82 patients (48.8%). Of the 82 patients with an allergic-like reaction, 28 (34.1%) received a gadolinium-based contrast agent before and had no reaction. A total of 12 of 33 (36.4%) breakthrough reactions occurred, and there were 15 of 96 (15.6%) reactions with a delayed onset. Conclusion The frequency of allergic-like reactions to gadobutrol is very low, accounting for 96 reactions among 30 373 gadobutrol-enhanced MR imaging examinations (0.32%), and severe reactions are rare. In patients who experience a reaction, breakthrough reactions and delayed reactions are relatively common. (©) RSNA, 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27110731     DOI: 10.1148/radiol.2016151066

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  9 in total

1.  Contrast Medium Hypersensitivity: A Large Italian Study with Long-Term Follow-Up.

Authors:  Eleonora Nucera; Giuseppe Parrinello; Sebastiano Gangemi; Alessandro Buonomo; Arianna Aruanno; Franziska Michaela Lohmeyer; Riccardo Inchingolo; Angela Rizzi
Journal:  Biomedicines       Date:  2022-03-24

Review 2.  The Use of Electronic Health Records to Study Drug-Induced Hypersensitivity Reactions from 2000 to 2021: A Systematic Review.

Authors:  Fatima Bassir; Sheril Varghese; Liqin Wang; Yen Po Chin; Li Zhou
Journal:  Immunol Allergy Clin North Am       Date:  2022-03-31       Impact factor: 3.152

3.  Patterns of use, effectiveness and safety of gadolinium contrast agents: a European prospective cross-sectional multicentre observational study.

Authors:  Jarl Åsbjørn Jakobsen; Carlo Cosimo Quattrocchi; Frank H H Müller; Olivier Outteryck; Andrés Alcázar; Wolfgang Reith; Patricia Fraga; Valeria Panebianco; Alexis Sampedro; Radoslaw Pietura
Journal:  BMC Med Imaging       Date:  2021-04-20       Impact factor: 1.930

Review 4.  Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration.

Authors:  Julie Davies; Petra Siebenhandl-Wolff; Francois Tranquart; Paul Jones; Paul Evans
Journal:  Arch Toxicol       Date:  2022-01-08       Impact factor: 5.153

5.  Hypersensitivity to Gadolinium-Based Contrast Media.

Authors:  M Teresa Gracia Bara; Alicia Gallardo-Higueras; Esther M Moreno; Elena Laffond; Francisco J Muñoz Bellido; Cristina Martin; Miriam Sobrino; Eva Macias; Sonia Arriba-Méndez; Rosita Castillo; Ignacio Davila
Journal:  Front Allergy       Date:  2022-03-17

6.  The Emerging Role of MR Urography in Imaging Megaureters in Children.

Authors:  Dominik Świȩtoń; Małgorzata Grzywińska; Piotr Czarniak; Andrzej Gołȩbiewski; Agata Durawa; Jacek Teodorczyk; Mariusz Kaszubowski; Maciej Piskunowicz
Journal:  Front Pediatr       Date:  2022-03-23       Impact factor: 3.418

7.  Gadolinium-based contrast agents for imaging of the central nervous system: A multicenter European prospective study.

Authors:  Ashkan Heshmatzadeh Behzadi; Jennifer McDonald
Journal:  Medicine (Baltimore)       Date:  2022-08-26       Impact factor: 1.817

8.  Fatal anaphylactic reaction to intravenous gadobutrol, a gadolinium-based MRI contrast agent.

Authors:  Sabine Franckenberg; Florian Berger; Sarah Schaerli; Garyfalia Ampanozi; Michael Thali
Journal:  Radiol Case Rep       Date:  2017-11-01

Review 9.  Gadobutrol: A Review in Contrast-Enhanced MRI and MRA.

Authors:  Lesley J Scott
Journal:  Clin Drug Investig       Date:  2018-08       Impact factor: 2.859

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.